Gene · 10769
PLK2: polo like kinase 2
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. PLK2: polo like kinase 2. Genes, record 10769. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10769
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9NYY3 | Serine/threonine-protein kinase PLK2 | 685 | 7 | Ensembl, GeneID, HGNC |
Source UniProt
Patents33
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026013165 A1 | 2026-01-15 | 4 | Q9NYY3 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 58303 | Q9NYY3 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 2898 | Q9NYY3 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 2898 | Q9NYY3 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 33650 | Q9NYY3 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 33650 | Q9NYY3 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 33650 | Q9NYY3 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 64475 | Q9NYY3 | Espacenet |
| JP 2022092366 A | 2022-06-22 | 637 | Q9NYY3 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 167446 | Q9NYY3 | Espacenet |
1 to 10 of 33
See all 33 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,049
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PLK2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 13 | 2025 |
| ZIABC010681 | Development of inhibitors targeting Plk1 polo-box domain | 13 | 2025 |
| ZIABC006198 | Inhibitors of Tyrosine Kinase-Dependent Signaling as Anti-Cancer Agents | 10 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 7 | 2025 |
| P30CA051008 | Georgetown University Lombardi Comprehensive Cancer Center Support Grant | 6 | 2025 |
| T32ES007015 | Molecular & Environmental Toxicology Predoctoral Training Program | 4 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 3 | 2025 |
| P30CA014051 | Cancer Center Support (Core) Grant | 3 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 3 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,049Source NIH's project files
See all 1,049 nih grantsPapers1,578
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discovery of novel pyrazolo[3,4-d]pyrimidine-6-amine derivatives as potent polo-like kinase 2 inhibitors. | Eur J Med Chem | 2026 | 42700477 | PubTator, text mining | PubMed |
| Integrated Transcriptomic and Functional Profiling Reveals IL-7R/FOXO1 Axis as a Target of Momordicine I in Meningioma. | Anticancer Agents Med Chem | 2026 | 42634359 | PubTator, text mining | PubMed |
| RETRACTION: PLK2 Phosphorylates and Inhibits Enriched TAp73 in Human Osteosarcoma Cells. | Cancer Med | 2026 | 42286441 | PubTator, text mining | PubMed |
| Phosphoproteomic and kinase networks reveal partial EMT and stress-adaptive growth programs in pediatric Peutz-Jeghers polyps. | Pediatr Res | 2026 | 42082734 | PubTator, text mining | PubMed |
| Authentic Phosphorylation of α-Synuclein at Ser129 Reveals Functional Differences Not Captured by the S129D Phosphomimetic. | ACS Chem Biol | 2026 | 42024867 | PubTator, text mining | PubMed |
| A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English. | J Vis Exp | 2026 | 42008362 | PubTator, text mining | PubMed |
| DYRK1A and Parkinson's disease, facts and hypotheses. | Neurobiol Dis | 2026 | 41991085 | PubTator, text mining | PubMed |
| A pathogenic Tau mutation drives autophagy-lysosome dysfunction that limits Tau degradation in a model of frontotemporal dementia. | Nat Commun | 2026 | 41916975 | PubTator, text mining | PubMed |
| Exploring Centrosome Amplification-Associated Biomarkers in Osteoarthritis Through Bioinformatics and Experimental Approaches. | J Inflamm Res | 2026 | 41907222 | PubTator, text mining | PubMed |
| RNA N6-methyladenosine (m6A) regulates cell cycle progression in diffuse midline glioma (DMG) and confers sensitivity to FTO inhibition. | Cell Death Dis | 2026 | 41888518 | PubTator, text mining | PubMed |
1 to 10 of 1,578
See all 1,578 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10769
GET https://conductscience.org/api/genes/v1/10769/patents?page=2